First principle
A posted price is only a starting point.
Ibogaine programs are not standardized products, and public price figures are generally clinic- or industry-published estimates rather than government-verified averages. They can describe very different lengths of stay, locations, monitoring arrangements, accommodation, and aftercare. The price may be bundled, partly bundled, or only the base program charge.
For a broader starting point on ibogaine policy and access questions, keep legal status, program marketing, and individual medical decisions separate. Ibogaine itself has not been approved by the U.S. Food and Drug Administration for medical use; the agency’s drug development and approval process explains why approval status matters when interpreting treatment claims.
This page is a planning framework, not a market survey or clinical recommendation. Start with the wider context on ibogaine costs, safeguards, and practical planning, then use the line items below to compare written quotes on like-for-like terms.